Wednesday, January 31, 2018 8:54:54 AM
January 31, 2018
Tags: NewsPoints Cascadian Seattle Genetics United States Corporate Affairs Mergers &
Acquisitions
A group of Cascadian Therapeutics Inc. shareholders are attempting
to block the $300 million purchase of the company by Seattle Genetics.
The shareholders allege that the purchase price of $10 per share is insufficient in light of the company's growth prospects, and that deal-protection clauses in the merger agreement preclude other
companies from submitting successful competing offers. Indeed the company has over $100 million of cash on its balance sheet or $2 cash per share and no debt. In addition, shareholders allege that senior management obtained personal benefits for their own self interests in agreeing to sell the company that are not being shared with common stockholders.
Cascadian did not immediately respond to requests for a comment.
To contact the law firm on behalf of shareholders of
Cascadian for more information as to how you can participate with other shareholders for a higher price at no cost or expense call toll free 800.511.7037 or contact@tripplevy.com
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM